Berry Genomics Co.,Ltd: what insiders have been doing
This page follows insider dealings at Berry Genomics Co.,Ltd as filed with SSE / SZSE (CSRC), a company from the Health Care sector. From 4 November 2025 to 4 November 2026, the disclosure feed for Berry Genomics Co.,Ltd logged 2 filings by 1 insider.
The flow runs one way only: 2 sales worth €1.3M, from 1 insider, and no purchase. The largest single trade was a sale of €1.2M by 高扬, published on 9 April 2026.
Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Across the 521 companies tracked on its exchange, the median is 2 filings; at 2 filings, this issuer sits right on that mark. Over the whole record (from 2025), the tally stands at no purchases and 4 sales.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and UCB. This summary is built from SSE / SZSE (CSRC) disclosures alone and does not predict where the share price will go.
Who traded when
BuySaleThis score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 98,000 shares10.0% of flowA股XSHESZSE:273000000602310430
- 906,500 shares89.3% of flowA股XSHESZSE:273000000358316260
- 0A股XSHESZSE:173000009014571360
- 1,200 shares0.2% of flowA股XSHESZSE:173000008997137900
- 3,800 shares0.5% of flowA股XSHESZSE:173000008994581820
5 of 5 declarations
About Berry Genomics Co.,Ltd
贝瑞基因 is a company specializing in the health and pharmaceutical sector, providing genomic and diagnostic services. It is listed on the XSHE market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
